Sanofi (SNY)

49.58
0.31 0.62
NASDAQ : Health Technology
Prev Close 49.89
Open 49.58
Day Low/High 49.37 / 49.93
52 Wk Low/High 37.62 / 51.84
Volume 1.61M
Avg Volume 2.61M
Exchange NASDAQ
Shares Outstanding 2.51B
Market Cap 124.08B
EPS 1.30
P/E Ratio 26.61
Div & Yield 1.17 (2.39%)

Here's What's Driving Biotech

And it's not the favorable macroeconomic climate.

Gilead May Be the Cure for the Blues

Gilead May Be the Cure for the Blues

Gilead's Relative Strength Index slope is very strong.

Gilead May Be the Cure for the Blues

Gilead May Be the Cure for the Blues

Gilead's Relative Strength Index slope is very strong.

That's Just What's Supposed to Happen

Stocks that stabilized yesterday were terrific today.

Growth Seekers Return

Investors are seeing growth today in three areas.

Picking Up Where We Left Off

Picking Up Where We Left Off

Another quarter, another run to record highs.

Consider These Three French Companies

Consider These Three French Companies

These firms offer strong dividends, cash flow and trailing 12-month sales.

The Day Ahead: Just Another Muted Monday

The Day Ahead: Just Another Muted Monday

Welcome to another holiday-shortened week.

Is There Still a Play to Be Made on Regeneron?

Is There Still a Play to Be Made on Regeneron?

An inverse head and shoulders pattern could soon develop.

Unilife Strutting Over Sanofi Deal

Unilife Strutting Over Sanofi Deal

Syringe-seller Unilife is gaining momentum - and scaring the shorts - after signing a big deal with Sanofi, says Alan Shortall, CEO of Unilife.

Europe Makes a Comeback

Europe Makes a Comeback

When economic news is good, so are investment prospects

This Is Incredibly Bullish Behavior

This Is Incredibly Bullish Behavior

Most stocks seem unable to stop once propelled higher.

Small IPOs Bring Risks

Small IPOs Bring Risks

Gladstone Land, KaloBios Pharmaceuticals and Stemline Therapeutics plan to go public, IPO Desktop President Francis Gaskins isn't sure the risk is worth it.

Blown Away by Transports, Drugs

Blown Away by Transports, Drugs

Not so much by the financials.

Don't Wait to Buy Wells Fargo, Sanofi

Don't Wait to Buy Wells Fargo, Sanofi

Jeanie Wyatt, CEO of South Texas Money Management, names her favorite stocks including Wells Fargo and Sanofi.

Europe: Down but Not Out

Europe: Down but Not Out

Despite the economic travails, it has companies that are doing well.

3 Cancer-Drug Stocks Look Strong

3 Cancer-Drug Stocks Look Strong

These drug companies addressing prostate cancer get high grades from my guru strategies.

Sour on Sanofi

Sour on Sanofi

This drugmaker has fallen from a nine-month high to a key support level in just five sessions.

Two Drug Stocks Offer Trade Setups

Two Drug Stocks Offer Trade Setups

Forest Labs has potential volatility and high short interest, and Sanofi has crossed some key levels.

Buy SNY under $35

Buy SNY under $35

Stephanie Link, director of research for TheStreet, explains why Sanofi is an attractive investment under $35.

3 Stocks I Saw on TV, January 30

3 Stocks I Saw on TV, January 30

Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Sanofi-Aventis, Cypress Semiconductor and Biogen.

A Prescription for Growth

A Prescription for Growth

In the large, but targeted, market for diabetes drugs, two very different companies share a deeper commitment.

The Day Ahead: Anticipating Economic Data

The Day Ahead: Anticipating Economic Data

European headlines worried traders ahead of the open, as they await a raft of economic and retail reports.

Safe Stocks for Your Income Portfolio

Safe Stocks for Your Income Portfolio

If you need to live on investment income, bonds and CDs are not enough -- you need dividends.

Temper Your Optimism

Temper Your Optimism

Set your portfolio up with both long and short exposure in case of a series of bank failures.

This CEO Gets It

Sanofi's chief executive knows what real investors, not hedge funds, want.